Le Lézard
Classified in: Health
Subject: PER

Lisa Genova, Ph.D joins CereVasc Board of Directors


BOSTON, Jan. 16, 2019 /PRNewswire/ -- CereVasc, LLC, a company focused on improving the care of patients with communicating hydrocephalus announced today the addition of acclaimed neuroscientist and author Lisa Genova, Ph.D., to the Board of Directors. 

Dr. Genova is the New York Times bestselling author of several novels inspired by neuroscience and the human spirit. Her works include Still Alice, which was adapted into an Oscar winning film by the same name, Left Neglected, Love Anthony, Inside the O'Briens, and Every Note Played.

"We are delighted to have Lisa join our team. Lisa's graduate training in neuroscience combined with her expertise and knowledge of neurodegenerative disease will be very valuable to CereVasc as we continue to pursue evidence to support use of our technology in treating dementia associated with normal pressure hydrocephalus, future application of our technology in delivery of therapeutic agents directly to the central nervous system, and further evaluate the use of our approach in treating other neurodegenerative diseases," said Dan Levangie, Chairman & CEO of CereVasc, LLC.

"CereVasc's vision for cerebrospinal fluid management is unique, innovative, and important for patients," said Dr. Genova. "I look forward to working with CereVasc in advancing their technology as we strive to treat a variety of brain disorders."

Dr. Genova graduated valedictorian from Bates College with a degree in biopsychology and holds a Ph.D. in neuroscience from Harvard University. She travels worldwide speaking about the neurological diseases she writes about and has appeared on The Dr. Oz Show, TodayPBS NewsHour, CNN, and NPR. Her TED talk, What You Can Do To Prevent Alzheimer's, has been viewed more than 3.5 million times.

Lisa was named one of the U.S. Top 50 Influencers in Aging by Next Avenue. She received The Pell Center Prize for Story in the Public Square, for "distinguished storytelling that has enriched the public dialogue," The Sargent and Eunice Shriver Profiles in Dignity Award, the National Alzheimer's Association's Rita Hayworth Award, The Global Genes RARE Champions of Hope Award, and The American College of Neuropsychopharmacology Media Award for "informing the public about Treatment and ongoing research in medical illness."

About CereVasc, LLC
CereVasc, LLC is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. The Company's first product, the eShunttm System, is an endovascularly deliverable cerebrospinal fluid shunt and associated delivery componentry designed to avoid the need for invasive surgery, general anesthesia and hospitalization associated with the current surgical treatment of communicating hydrocephalus using ventriculo-peritoneal shunts.

SOURCE CereVasc, LLC


These press releases may also interest you

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...

at 16:35
Tilray Brands, Inc. , a leader in the craft beer and cannabis-lifestyle industries, celebrates high honors and awards at the 2024 Craft Brewer's Conference and World Beer Cup. 10 Barrel Brewing won four craft beer awards and 10...

at 16:34
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular...

at 16:30
In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira® biosimilar available for $0 out of pocket for eligible...

at 16:28
Dr. Siva Mohan, Co-Founder and Chief Medical Officer of RazorMetrics, an Austin-based drug cost reduction platform, is the Best Entrepreneur - Health Products & Services Status: Silver Stevie Winner from the American Business Awards. The Stevie®...

at 16:20
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity ...



News published on and distributed by: